Amundi
PCRX icon

Amundi’s Pacira BioSciences PCRX Stock Holding History

Amundi’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Buy
+13,684
New +$304K ﹤0.01% 1733
2025
Q2 		– Sell
-18,723
Closed -$455K – 2040
2025
Q1 		$455K Sell
18,723
-4,391
-19% -$105K ﹤0.01% 1512
2024
Q4 		$429K Buy
23,114
+15,431
+201% +$271K ﹤0.01% 1591
2024
Q3 		$120K Buy
7,683
+711
+10% +$12.2K ﹤0.01% 1755
2024
Q2 		$151K Buy
+6,972
New +$198K ﹤0.01% 1633
2022
Q4 		– Sell
-2,635
Closed -$149K – 1957
2022
Q3 		$149K Hold
2,635
– – ﹤0.01% 1498
2022
Q2 		$139K Hold
2,635
– – ﹤0.01% 1400
2022
Q1 		$214K Hold
2,635
– – ﹤0.01% 1380
2021
Q4 		$162K Hold
2,635
– – ﹤0.01% 1507
2021
Q3 		$148K Hold
2,635
– – ﹤0.01% 1476
2021
Q2 		$160K Buy
+2,635
New +$167K ﹤0.01% 1422

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return